Sunitinib malate is under clinical development by Pfizer and currently in Phase II for Papillary Thyroid Cancer. According to GlobalData, Phase II drugs for Papillary Thyroid Cancer have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sunitinib malate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sunitinib malate overview
Sunitinib malate (Sutent, SU011248) is an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Sunitinib malate is indicated for the treatment of gastrointestinal stromal tumors (GIST), advanced cholangiocarcinoma, renal cell carcinoma, islet cell carcinoma, pancreatic neuroendocrine tumor and metastatic renal cell carcinoma.
The drug candidate is under development for the treatment of renal cell carcinoma as an adjuvant therapy, refractory or progressive high grade glioma and ependymoma tumors, thymoma, thymic carcinoma, metastatic mucosal or acral lentiginous melanoma, cholangiocarcinoma, uveal melanoma, follicular thyroid cancer, papillary thyroid cancer, recurrent glioblastoma multiforme, unresectable malignant pheochromocytoma, and paraganglioma. It was also under development for ependymoma, high-grade glioma, HER2- breast cancer, HER-2 positive breast cancer, triple-negative breast cancer, metastatic hepatocellular carcinoma, metastatic breast cancer, non-small cell lung cancer, transitional cell carcinoma of bladder, small-cell lung cancer, anaplastic astrocytoma, prostate cancer, colorectal cancer, soft tissue sarcoma including liposarcoma, metastatic melanoma, leiomyosarcoma, pediatric GIST, fibrosarcoma, malignant fibrous histiocytoma, meningioma, meurofibromatoses type I and II, Von Hippel-Lindau syndrome and germ cell tumors as third line therapy.
Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Sunitinib malate’s drug-specific PTSR and LoA scores, buy the report here.